Arcutis Biotherapeutics annual revenue
2020
2021
2022
2023
2024
2025
Arcutis Biotherapeutics reported $372.1M in revenue for fiscal 2025, an increase of 123.41% from the previous fiscal year.
View full Arcutis Biotherapeutics company overview| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $372.1M | $205.5M | +123.41% |
| 2024 | 2024-12-31 | $166.5M | $137.4M | +470.62% |
| 2023 | 2023-12-31 | $29.2M | $25.5M | +691.81% |
| 2022 | 2022-12-31 | $3.7M | $3.7M | — |
| 2021 | 2021-12-31 | $0 | $0 | — |
| 2020 | 2020-12-31 | $0 | — | — |
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $129.9M | $48.4M | +59.33% |
| Q1 2026 | 2026-03-31 | $105.4M | $41.6M | +65.08% |
| Q4 2025 | 2025-12-31 | $127.5M | $58.1M | +83.83% |
| Q3 2025 | 2025-09-30 | $99.2M | $54.5M | +121.69% |
| Q2 2025 | 2025-06-30 | $81.5M | $50.6M | +164.13% |
| Q1 2025 | 2025-03-31 | $63.8M | $42.3M | +196.01% |
| Q4 2024 | 2024-12-31 | $69.4M | $55.8M | +412.79% |
| Q3 2024 | 2024-09-30 | $44.8M | $36.6M | +451.92% |
| Q2 2024 | 2024-06-30 | $30.9M | $26.1M | +546.92% |
| Q1 2024 | 2024-03-31 | $21.6M | $18.8M | +675.58% |
| Q4 2023 | 2023-12-31 | $13.5M | $10.6M | +356.81% |
| Q3 2023 | 2023-09-30 | $8.1M | $7.4M | +1018.48% |
| Q2 2023 | 2023-06-30 | $4.8M | $4.8M | — |
| Q1 2023 | 2023-03-31 | $2.8M | $2.8M | — |
| Q4 2022 | 2022-12-31 | $3.0M | — | — |
| Q3 2022 | 2022-09-30 | $725,000 | $725,000 | — |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q1 2022 | 2022-03-31 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $0 | — | — |
Arcutis Biotherapeutics's latest reported quarter, Q2 2026, generated $129.9M in revenue, an increase of 59.33% year over year.
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Arcutis Biotherapeutics source filings ↗